Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2010-10-29 Share Issue/Capital Cha…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Increased number of shares and votes in Medivir
Share Issue/Capital Change Classification · 99% confidence The document is a short press release dated October 29, 2010, announcing a change in the total number of shares and votes due to the exercise of employee stock options. This directly relates to a change in the company's capital structure or share count. The most fitting category is 'Share Issue/Capital Change' (SHA), as the exercise of options increases the outstanding share count. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a dividend announcement (DIV) or director dealing (DIRS). Given the content, SHA is the precise classification.
2010-10-29 English
Medivir’s U.S. commercialisation partner Meda presents positive Xerese™ data at the AOA's Osteopathic Medical Conference and Exposition
Regulatory Filings Classification · 92% confidence The document is explicitly titled "Press Release, 26 October 2010" and announces that Medivir's partner, Meda, presented positive data for the drug Xerese™ at a medical conference. It details study results, provides information about the drug, and includes quotes from the CEO. This format—a formal announcement of recent business or clinical developments intended for the public and investors—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change notice (MANG), and it is a formal announcement of recent operational news, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS). Given the content focuses on clinical data presentation rather than quarterly financial performance highlights, and it is a general announcement, RNS is a strong candidate. However, press releases announcing significant clinical trial data or partnership updates are often categorized under ER if they are issued around earnings periods, or RNS if they are standalone. Since the definitions provided do not have a specific 'Press Release' category, and this is a formal announcement of operational news, RNS (Regulatory Filings / General Announcement) is the most appropriate fallback, although ER is plausible if this was part of a quarterly cycle. Given the lack of explicit quarterly financial figures, RNS is safer.
2010-10-26 English
Nomination Committee appointed for 2010-2011
Board/Management Information Classification · 95% confidence The document is a short press release dated October 25, 2010, announcing the appointment of a new Nomination Committee for the upcoming period (2010-2011). This committee is typically established in relation to the Annual General Meeting (AGM) process, as indicated by the reference to an 'AGM resolution'. Since the document is an announcement about the composition of a committee related to governance and shareholder representation, it falls under the scope of Board/Management Information (MANG) or potentially Governance Information (CGR). However, the specific focus on the Nomination Committee composition, which directly impacts board nominations and shareholder representation, aligns most closely with announcements regarding management/board structure changes or governance bodies. Given the options, MANG (Board/Management Information) is the most appropriate fit for announcing the composition of a key governance/nomination body, although CGR is also plausible. Since it is a direct announcement about the composition of a committee responsible for board nominations, MANG is selected.
2010-10-25 English
Valberedningen utsedd för 2010-2011
Board/Management Information Classification · 95% confidence The document is a press release dated October 25, 2010, announcing the appointment of the Nomination Committee ('Valberedningen utsedd för 2010-2011'). The text details the composition of the committee, which includes representatives from major shareholders and the chairman of the board. This type of announcement, concerning the composition of the body responsible for nominating board members and auditors, falls under governance or board-related information. While it is not explicitly a change in senior management (MANG), it is directly related to the composition and governance structure of the board's nomination process. Given the options, 'Governance Information' (CGR) is the most appropriate fit as it deals with internal rules and board structure practices, specifically the nomination process for future board members. It is not an AGM presentation (AGM-R), a director dealing report (DIRS), or a general regulatory filing (RNS), as it concerns a specific governance function.
2010-10-25 Swedish
Interim / Quarterly Report 2010
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period 1 January to 30 September 2010. It contains comprehensive financial data, including income statements, cash flow, and balance sheet summaries, as well as detailed management commentary on business operations, clinical trials, and future outlook. It is not a short announcement, but the full report itself, fitting the definition of an Interim/Quarterly Report. 9M 2010
2010-10-22 Swedish
Interim / Quarterly Report 2010
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report, 1 January – 30 September 2010' and contains comprehensive financial highlights, operational updates, and detailed R&D portfolio information for a period shorter than a full fiscal year. It provides substantive financial data and analysis rather than just an announcement or certification. Therefore, it is classified as an Interim/Quarterly Report. 9M 2010
2010-10-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.